Vitamin D Supplementation and Glycemic Outcomes
- Conditions
- Insulin Resistance
- Interventions
- Dietary Supplement: cholecalciferol (Euro-Pharm International, Canada)
- Registration Number
- NCT02942732
- Lead Sponsor
- Université d'Auvergne
- Brief Summary
The investigators examined the effect of vitamin D supplementation on glucose homeostasis and metabolic markers in healthy normal weight and overweight young subjects and healthy normal-weight and overweight elderly subjects living in Beirut, Lebanon.
- Detailed Description
A low serum 25-hydroxyvitamin D (25(OH)D) concentration has been shown to correlate with higher fasting blood glucose (FBG) and insulin levels and other metabolic abnormalities like dyslipidemia. Previous studies suggest that vitamin D supplementation is able to improve insulin sensitivity and metabolic markers. The aim of the study was to investigate the effect of vitamin D supplementation on glucose homeostasis and metabolic markers in healthy normal weight and overweight young subjects and healthy normal-weight and overweight elderly subjects living in Beirut, Lebanon. Participants (n= 180; 93 men and 87 women) deficient in vitamin D were recruited from Saint Charles Hospital, Beirut, Lebanon. Four groups were recruited: normal-weight adults (n=30, age ≤ 65 years and BMI \< 25 kg/m²), overweight adults (n=30, age ≤ 65 years and BMI ≥ 25 kg/m²), normal-weight elderly (n=60, age ≥ 65 years and BMI \< 25 kg/m²) and overweight elderly (n=60, age ≥ 65 years and BMI ≥ 25 kg/m²).
Participants received a supplement of 10,000 IU cholecalciferol to be taken three times per week for a period of 6 months. Glucose homeostasis and metabolic markers were measured at start of treatment, at 3 months and at 6 months.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 180
- Participants with no medical history of congestive heart failure, acute heart insufficiency and renal failure were included
- Participants with medical history of congestive heart failure, acute heart insufficiency and renal failure were excluded
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description normal-weight elderly cholecalciferol (Euro-Pharm International, Canada) normal-weight elderly (n=60, age ≥ 65 years and BMI ≤ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months. overweight adult subjects cholecalciferol (Euro-Pharm International, Canada) overweight adult subjects (n=30, age ≤ 65 years and BMI ≥ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months. overweight elderly cholecalciferol (Euro-Pharm International, Canada) overweight elderly (n=60, age ≥ 65 years and BMI ≥ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months. normal-weight adult subjects cholecalciferol (Euro-Pharm International, Canada) normal-weight adult subjects (n=30, age ≤ 65 years and BMI ≤ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
- Primary Outcome Measures
Name Time Method Fasting blood glucose (mmol/l) Baseline and 6 months Change in Fasting blood glucose in mmol/l
HbA1C (%) Baseline and 6 months Change in HbA1C (%)
Fasting Insulin (mIU/L) Baseline and 6 months Change in Fasting Insulin (mIU/L)
HOMA-IR Baseline and 6 months Change in HOMA-IR
- Secondary Outcome Measures
Name Time Method